| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
13.58(B) |
| Last
Volume: |
397,145 |
Avg
Vol: |
427,539 |
| 52
Week Range: |
$276.47 - $410 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1207 |
| Guru Rank Value : -1 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
106,181 |
238,115 |
680,945 |
1,453,774 |
| Total Sell Value |
$32,096,060 |
$78,012,164 |
$234,368,691 |
$425,936,569 |
| Total People Sold |
6 |
9 |
13 |
13 |
| Total Sell Transactions |
14 |
31 |
106 |
225 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-06-26 |
4 |
AS |
$284.10 |
$3,142,718 |
D/D |
(11,000) |
36,781 |
|
0% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-06-26 |
4 |
OE |
$135.42 |
$1,489,620 |
D/D |
11,000 |
47,781 |
|
- |
|
| Giltner Richard |
|
– • – |
2025-06-24 |
4 |
S |
$289.60 |
$879,214 |
D/D |
(3,036) |
19,384 |
|
2% |
|
| Giltner Richard |
|
– • – |
2025-06-24 |
4 |
OE |
$175.43 |
$877,150 |
D/D |
5,000 |
22,420 |
|
- |
|
| Mesa Nilda |
|
– • – |
2025-06-24 |
4 |
S |
$289.99 |
$187,045 |
D/D |
(645) |
4,883 |
|
2% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-06-12 |
4 |
AS |
$275.98 |
$3,079,514 |
D/D |
(11,000) |
36,781 |
|
-1% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-06-12 |
4 |
OE |
$135.42 |
$1,489,620 |
D/D |
11,000 |
47,781 |
|
- |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-06-09 |
4 |
AS |
$325.20 |
$3,904,496 |
D/D |
(12,000) |
8,118 |
|
-13% |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-06-09 |
4 |
OE |
$117.76 |
$1,413,120 |
D/D |
12,000 |
20,118 |
|
- |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-06-02 |
4 |
AS |
$325.54 |
$3,909,893 |
D/D |
(12,000) |
8,118 |
|
-13% |
|
| Edgemond James |
CFO AND TREASURER |
• – – |
2025-06-02 |
4 |
OE |
$117.76 |
$1,413,120 |
D/D |
12,000 |
20,118 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-05-29 |
4 |
AS |
$311.14 |
$3,476,765 |
D/D |
(11,000) |
36,781 |
|
-11% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-05-29 |
4 |
OE |
$117.76 |
$1,418,980 |
D/D |
11,000 |
47,781 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-05-15 |
4 |
AS |
$293.31 |
$3,246,150 |
D/D |
(11,000) |
36,781 |
|
-6% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-05-15 |
4 |
OE |
$117.76 |
$1,295,360 |
D/D |
11,000 |
47,781 |
|
- |
|
| Thompson Tommy G |
|
– • – |
2025-05-09 |
4 |
S |
$305.15 |
$762,865 |
D/D |
(2,500) |
8,480 |
|
6% |
|
| Thompson Tommy G |
|
– • – |
2025-05-09 |
4 |
OE |
$175.43 |
$438,575 |
D/D |
2,500 |
10,980 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-05-01 |
4 |
AS |
$295.12 |
$3,310,201 |
D/D |
(11,000) |
36,781 |
|
-3% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-05-01 |
4 |
OE |
$117.76 |
$1,295,360 |
D/D |
11,000 |
47,781 |
|
- |
|
| Dwek Raymond |
|
– • – |
2025-04-21 |
4 |
AS |
$285.57 |
$856,710 |
D/D |
(3,000) |
1,750 |
|
0% |
|
| Dwek Raymond |
|
– • – |
2025-04-21 |
4 |
OE |
$175.43 |
$526,290 |
D/D |
3,000 |
4,750 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-04-17 |
4 |
AS |
$280.35 |
$3,121,543 |
D/D |
(11,000) |
36,781 |
|
-0% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2025-04-17 |
4 |
OE |
$117.76 |
$1,295,360 |
D/D |
11,000 |
47,781 |
|
- |
|
| Dwek Raymond |
|
– • – |
2025-04-14 |
4 |
AS |
$285.16 |
$855,480 |
D/D |
(3,000) |
1,750 |
|
-0% |
|
| Dwek Raymond |
|
– • – |
2025-04-14 |
4 |
OE |
$175.43 |
$526,290 |
D/D |
3,000 |
4,750 |
|
- |
|
2360 Records found
|
|
Page 1 of 95 |
|
|
3.08 (1.08%) 
